Newsroom

Ten years ago, a seminal paper published by Cytel Founder Cyrus Mehta, introduced the Promising Zone Design to..

When selecting clinical trial designs, how many design options should a sponsor explore? Would a sponsor feel more..

For many decades the Pareto Frontier has been employed by actors in the private sector to evaluate and understand the..

When developing clinical strategy, applying familiar business principles to the specific requirements of clinical..

As healthcare systems across the world, continue to grapple with the pressures of COVID-19, Cytel advances yet another..

Recently, Cytel co-founder Professor Cyrus Mehta noted that, “Clinical trial design selection is too much like an art,..

The urgent need to discover and assess the efficacy and safety of COVID-19 vaccine candidates will affect the future..

Bayesian models offer a flexible way of incorporating historical controls in the analysis of trial data (whether single..

As Chief Scientific Officer, Dr. Yannis Jemiai plays a pivotal role in maintaining Cytel’s well-established reputation..